HCPLive Network

FDA Bars Generic Version of Oxycontin

On April 16, 2013, the US Food and Drug Administration (FDA) announced that, “because original OxyContin provides the same therapeutic benefits as reformulated OxyContin, but poses an increased potential for certain types of abuse, the FDA has determined that the benefits of original OxyContin no longer outweigh its risks.” Noting that original OxyContin was “withdrawn from sale for reasons of safety or effectiveness,” the FDA announced that it “will not accept or approve any abbreviated new drug applications (generics) that rely upon the approval of original OxyContin.”
 
Simply put, the FDA has decided that generic forms of the original formulation of OxyContin will not be allowed in the US market, period. The original form of OxyContin has been replaced by reformulated OxyContin (OxyNEO in Canada). This will mean that “hardened” forms of oxycodone and other extended-release (ER) or long-acting (LA) opioids will likely be required to employ “safety” features to be sold in the US.
 
Attempts to bring lower-cost generics, or alternative forms of controlled-release oxycodone to the US market will require competing manufacturers to utilize safety mechanisms such as incorporating multiple polymers to prevent users from crushing the pills into a fine powder, adding components to create gelling if added to water, or employing an opioid antagonist or some type of irritant in the medication to make misuse or abuse a very unpleasant experience.
 
The April 16 FDA press release also recognized the changes made by Purdue Pharma to “harden” reformulated OxyContin, and granted permission for a label change indicating “the product has physical and chemical properties that are expected to make abuse via injection difficult and to reduce abuse via the intranasal route (snorting).” This is the first time the FDA has permitted a drug manufacturer to state that a narcotic medication has tamper-resistant properties.
 
Douglas Throckmorton, MD, deputy director for regulatory programs in the FDA’s Center for Drug Evaluation and Research said, “The development of abuse-deterrent opioid analgesics is a public health priority for the FDA,” and that while “both original and reformulated OxyContin are subject to abuse and misuse, the FDA has determined that reformulated OxyContin can be expected to make abuse by injection difficult and [be] expected to reduce abuse by snorting compared to original OxyContin.”
 
It will be interesting to see whether the FDA makes a similar ruling regarding Endo Pharmaceuticals and Opana. The New York Times recently reported that Endo “has also petitioned the FDA seeking a similar claim of abuse resistance for a newer version of one of its drugs, Opana. If that claim proves successful, generic versions of the original form of Opana would also be barred.” The NYT article also stated that “Over the last year, Purdue Pharma and Endo have pushed for federal legislation that would require many opioids to be tamper-resistant, and lobbied in favor of similar state laws.”
 
This decision is likely to create pressure on all makers of ER/LA opioids to incorporate abuse-resistant or abuse-deterrent features in their medications. Currently, there is a four-year Risk Evaluation and Mitigation Strategy (REMS) effort to train 320,000 US prescribers to better screen and treat pain sufferers with opioid analgesics. Together, the new push for “hardened” medications and better prescribing practices may significantly reduce overdose deaths associated with opioid misuse and abuse.


B. Eliot Cole, MD, MPA, FAPA, CPE, is a member of the Pain Management editorial advisory board. He has served in executive positions for several prominent pain management organizations and societies, including the American Society of Pain Educators and the American Academy of Pain Management. He has been a pain management fellow, clinician, educator, and advocate for nearly 30 years and has practiced in a variety of settings serving a wide range of patients.

Further Reading
Concerned about a mysterious outbreak of pediatric paralysis, the US Centers for Disease Control and Prevention (CDC) has asked physicians to report any similar cases. In Denver, CO, 10 children have been admitted to Children’s Hospital Colorado with limb weakness and paralysis since Aug. 1, according to the hospital.
Work, non-work, and individual factors explain a considerable part of psychological distress, depression, and emotional exhaustion, according to a study published online July 24 in Social Psychiatry and Psychiatric Epidemiology.
For patients undergoing total knee arthroplasty, periarticular injection is superior to epidural analgesia for pain control, according to a study published in the Sept. 3 issue of The Journal of Bone & Joint Surgery.
The Centers for Medicare and Medicaid Services on Tuesday published a cache of physician payment data covering the last five months of 2013. The data is vast, but an early look at the site shows it has strengths and weaknesses.
Acupuncture doesn't improve knee pain any more than sham acupuncture, according to a new study published in the Oct. 1 issue of the Journal of the American Medical Association.
For millions of overweight Americans, regular exercise remains a prime weapon against excess weight and the threat of type 2 diabetes. However, a new study suggests that the battle may be tougher for some than for others, depending on their genes. The study was published online Sept. 29 in Diabetologia.
For patients with acute respiratory distress syndrome, simvastatin does not improve clinical outcomes, according to a study published online Sept. 30 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the European Society of Intensive Care Medicine, held from Sept. 27 to Oct. 1 in Barcelona, Spain.
More Reading